Celldex’s vaccine against the mutated epidermal growth factor receptor (EGFRvIII), reduced the risk of death from the disease by 47% in a 73-patient randomized Phase 2 study called ReACT. In addition, the survival rate at two years was 25% for patients given the vaccine versus none in the control group. It marks the first time an immunotherapy treatment has improved survival in a randomized trial of glioblastoma patients, researchers said. It is also among the first cancer vaccines to show a survival benefit. Continue reading →